Teva Gets FDA Nod to Market Generic Fosamax
February 7, 2008
Teva Pharmaceutical Industries has reported that the FDA has granted final approval for the company’s abbreviated new drug application to market its generic version of Merck’s osteoporosis treatment Fosamax tablets, 5mg, 10mg, 35mg, 40mg and 70mg.
As the first company to file an ANDA containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity. Shipment of the product will begin immediately.